Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$100,000.00

Liver as a bioreactor: Reinforcing mucosal immunity

EF 2020-21

Résumé
In six of the eight most recent global pandemics, the primary mode of pathogen transmission has been respiratory droplets. In seven of the pandemics, the route of entry has been at or across mucous membranes. Treatment of these infections with passive immunisation involves the isolation of serum from convalescent patients and transferring it to patients suffering from the disease. The procedure is based on the idea that convalescent patients have raised an immune response against the virus and their serum contains the necessary antibodies to fight-off infection. In theory, this makes for a compelling argument for passive immunisation, but in practice, isolating sufficient serum for large patient populations is generally considered infeasible, and unreliable due to donor variability of antibody specificity. Similarly, large-scale antibody manufacturing, is a fundamentally slow and laborious process with many hurdles leading to expensive treatments. Both of these approaches administer a type of antibody that largely remains in blood circulation and does not access the mucosa (site of entry for pathogens). Here, we use a more scalable, already established and approved method of nucleic acid delivery; we use lipid nanoparticles of messenger RNA, which are also the leading systems in coronavirus vaccine trials (Moderna, BioNTech). In this proposal, we deliver mRNA encoding a neutralising antibody, to a patient's liver cells which then produce and secrete the antibody into circulation. The liver produces over 80% of proteins in blood circulation and has the remarkable ability to produce antibodies also. We will deliver an antibody capable of increased accumulation in the lumen of the lungs (and other mucosa) as these regions are the primary sites of entry. The deliverable is a formulation that generates the antibody in the liver and affords robust protection (including for elderly or compromised patients) against the infection in the blood and at sites of pathogen entry.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Pennsylvania, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
441185
Name
Kulkarni Jayesh A
Region
Pennsylvania
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Liver as a bioreactor: Reinforcing mucosal immunity
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antibody Engineering; Lipid Nanoparticles; Liver As A Bioreactor; Mrna Therapy; Mucosal Immunity; Nucleoside-Modified Messenger Rna; Passive Immunization
Abstract
In six of the eight most recent global pandemics, the primary mode of pathogen transmission has been respiratory droplets. In seven of the pandemics, the route of entry has been at or across mucous membranes. Treatment of these infections with passive immunisation involves the isolation of serum from convalescent patients and transferring it to patients suffering from the disease. The procedure is based on the idea that convalescent patients have raised an immune response against the virus and their serum contains the necessary antibodies to fight-off infection. In theory, this makes for a compelling argument for passive immunisation, but in practice, isolating sufficient serum for large patient populations is generally considered infeasible, and unreliable due to donor variability of antibody specificity. Similarly, large-scale antibody manufacturing, is a fundamentally slow and laborious process with many hurdles leading to expensive treatments. Both of these approaches administer a type of antibody that largely remains in blood circulation and does not access the mucosa (site of entry for pathogens). Here, we use a more scalable, already established and approved method of nucleic acid delivery; we use lipid nanoparticles of messenger RNA, which are also the leading systems in coronavirus vaccine trials (Moderna, BioNTech). In this proposal, we deliver mRNA encoding a neutralising antibody, to a patient's liver cells which then produce and secrete the antibody into circulation. The liver produces over 80% of proteins in blood circulation and has the remarkable ability to produce antibodies also. We will deliver an antibody capable of increased accumulation in the lumen of the lungs (and other mucosa) as these regions are the primary sites of entry. The deliverable is a formulation that generates the antibody in the liver and affords robust protection (including for elderly or compromised patients) against the infection in the blood and at sites of pathogen entry.
Competitiondate
202012
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Kulkarni, Jayesh A
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~